| Quarter (USD) | Sep 24 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 69.29 mm | 69.29 mm | 69.29 mm | 69.29 mm | 69.29 mm | 69.29 mm |
| Cash burn (monthly) | 14.66 mm | 17.94 mm | 12.41 mm | 12.07 mm | (no burn) | 6.30 mm |
| Cash used (since last report) | 41.28 mm | 50.54 mm | 34.96 mm | 34.01 mm | n/a | 17.74 mm |
| Cash remaining | 28.01 mm | 18.76 mm | 34.33 mm | 35.29 mm | n/a | 51.55 mm |
| Runway (months of cash) | 1.9 | 1.0 | 2.8 | 2.9 | n/a | 8.2 |
| 13F holders | Current |
|---|---|
| Total holders | 130 |
| Opened positions | 54 |
| Closed positions | 18 |
| Increased positions | 46 |
| Reduced positions | 17 |
| 13F shares | Current |
|---|---|
| Total value | 459.67 bn |
| Total shares | 265.64 mm |
| Total puts | 142.20 k |
| Total calls | 3.10 k |
| Total put/call ratio | 45.9 |
| Largest owners | Shares | Value |
|---|---|---|
| VR Adviser | 16.22 mm | $38.27 bn |
| Venrock Healthcare Capital Partners III | 16.22 mm | $38.11 mm |
| Frazier Life Sciences Management | 16.22 mm | $38.27 bn |
| Suvretta Capital Management | 13.77 mm | $32.49 bn |
| Novartis Pharma | 12.31 mm | $69.91 mm |
| City Hill | 11.90 mm | $0.00 |
| Arch Venture | 11.06 mm | $26.09 bn |
| ARCH Venture Fund X | 11.06 mm | $172.25 mm |
| BLK BlackRock | 10.61 mm | $25.04 bn |
| Frazier Life Sciences Public Fund | 10.59 mm | $24.89 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 Jun 24 | Ebun Garner | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 160,082 | 324.97 k | 160,082 |
| 20 Jun 24 | David M. Chacko | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 278,812 | 565.99 k | 278,812 |
| 20 Jun 24 | Hambleton Julie | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 60,000 | 121.80 k | 60,000 |
| 20 Jun 24 | Multani Pratik S | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 60,000 | 121.80 k | 60,000 |
| 20 Jun 24 | Bristol James Arthur | Stock Option Common Stock | Grant | Acquire A | No | No | 2.03 | 60,000 | 121.80 k | 60,000 |
